06
Feb

After signing up to acquire Hospira for $17 billion, Pfizer is just getting started, analysts say, pointing to Pfizer’s failed quest for AstraZeneca as evidence that the drugmaker is looking for some transformational M&A.

…read more

Source: Pfizer’s still a likely buyer after its $17B ‘hors d’oeuvre’

    

0 No comments